

CollPlant Holdings Ltd.
("The Company")

December 27 2015

For the attention of
The Securities Authority
www.isa.gov.il

For the attention of
The Tel-Aviv Stock Exchange Ltd.
www.tase.co.il

Dear Sir or Madam

Subject: **Immediate Report**

The Company wishes to announce that CollPlant Ltd, a wholly owned subsidiary of the Company ("CollPlant") received notice from the European Patent Office that Fibrogen Inc. (the "Objector") has instituted proceedings opposition to the European patent issued in the name of CollPlant (the "Patent")¹. The Objector's argument is that the claims filed by CollPlant in the patent exceed the verbal support noted in the body of the patent and therefore are not new and they do not constitute inventive progress, as alleged in the opposition (the "opposition").

CollPlant's management is reviewing the opposition and taking measures to file its response to the opposition on the dates set. CollPlant is required to respond to the opposition by the set date and it intends doing so.

Based on the initial assessment of CollPlant's management and advisors with regard to the chance that Fibrogen Inc.'s opposition will be accepted, the Company estimates that the chances of the opposition being accepted are lower, inter alia, because the claims in the opposition are based, among other things, on documents of prior knowledge most of which were known to those testing the patent application and because such claims were raised by the Objector in the past with regard to another of CollPlant's patents, and were dismissed by the European Patent Office². In that case, the Objector's claims were dismissed, as aforesaid, and CollPlant was granted the patent in 2013. This file is still under the appeal proceedings at the European Patent Office.

¹ For further information regarding the patent see Series 1 in the table in section 17.4.1 (European Patent 2357241) in Chapter A of the Company's 2014 Periodic Report dated March 22, 2015 [Ref. No. 2015-01-057259] (the "Annual Report").

² See the Company's immediate report of July 22, 2013 (Reference No. 2013-01-097983), indicated herein by way of reference.

The assessments of the Company and of CollPlant with regard to the success rate of the opposition filed by the Objector against the validity of the patent in Europe is forward looking information, as defined in the Securities Law, 1968 and is not at all certain that it will materialize. In fact, it is not at all certain that the European Patent Office will indeed accept the foregoing opposition and this, among other things, because a substantive review of the material in the opposition file and a decision based on this material, indicate that the grounds in the opposition cannot lead to the cancellation of the foregoing European patent, due to policy or other considerations.

About CollPlant

CollPlant is a clinical-stage regenerative medicine company leveraging its proprietary, plant-based rhCollagen technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; Vergenix™BVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant's business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.